세계의 바이오뱅크 시장 예측(-2030년) : 오퍼링별, 운전 유형별, 워크플로우별, 샘플 유형별, 최종사용자별, 소유권별, 용도별, 유형별, 지역별

The biobanking market is projected to reach USD 11.82 billion by 2030 from USD 7.65 billion in 2025, at a CAGR of 9.1% during the forecast period. The growing focus on precision medicine and the expanding pipeline for cell and gene therapies are set to significantly fuel the growth of the biobanking market.

Precision medicine, which tailors treatments to individual genetic profiles, is increasingly driving the need for high-quality, well-preserved biological samples, as these form the foundation for personalized therapies. Additionally, the growing pipeline for cell and gene therapies is expected to be a major driver for the biobanking market in the coming years. The development of new cell and gene therapies, which often rely on stem cells, gene editing, and other advanced biotechnologies, necessitates storing and managing vast amounts of biological material. Biobanks are essential in supporting these therapies by providing a reliable and standardized platform for sample storage, processing, and distribution.

The physical biobanking segment accounted for the largest share of the biobanking services market in 2024.

Based on services, the biobanking market is segmented into physical biobanking, virtual biobanking, and other services. In 2024, the large share of physical biobanking services in the market can be attributed to the essential role they play in sample collection, storage, and preservation under controlled conditions. Physical biobanks offer the infrastructure necessary to store a wide range of biological samples, including blood, tissues, and DNA, in environments such as freezers, cryogenic tanks, and refrigerators, ensuring sample integrity for long-term use. As the demand for high-quality biological specimens grows, driven by advancements in precision medicine and genomics, physical biobanks are crucial for maintaining the stability and accessibility of these samples. Additionally, the ability to provide reliable, on-site sample management and real-time monitoring systems has further cemented the importance of physical biobanks in supporting pharmaceutical, biotechnology, and research sectors.

By ownership, the private/commercial providers segment accounted for the largest share of the market in 2024.

Based on the ownership model, the biobanking services market is segmented into private/commercial providers, academic & research institutional biobanks, national/regional agencies, hybrid/PPP (public-private-partnership) models, and other ownership models. In 2024, the private/commercial providers segment accounted for the largest share of the global biobanking market. The large share of the private/commercial providers model in the biobanking market is primarily driven by the growing demand for high-quality, scalable, and commercially viable biobanking solutions. These providers can offer advanced, state-of-the-art infrastructure and technology for sample storage, processing, and distribution, often tailored to meet the specific needs of pharmaceutical, biotechnology, and clinical research sectors. Commercial providers are also more agile in adopting innovations and expanding their services to meet the evolving demands of precision medicine, genomic research, and clinical trials. Their ability to provide comprehensive, end-to-end biobanking services and focus on efficiency and regulatory compliance has made them essential partners for organizations seeking reliable and standardized biological sample management. As a result, the private/commercial ownership model continues to dominate the market, with private players capturing a significant share.

The US dominated the biobanking market in 2024.

In 2024, the US held a significant share of the North American biobanking market, driven by its advanced healthcare infrastructure, substantial investment in research and development, and leading role in precision medicine. With numerous world-renowned academic institutions, pharmaceutical companies, and research organizations, the US is at the forefront of generating and utilizing biological samples for a wide range of scientific advancements. The growing emphasis on personalized medicine, genomics, and clinical trials has increased the demand for high-quality biobanks in the region. Additionally, favorable regulatory frameworks and substantial public and private funding continue to support the expansion of biobanking services, solidifying the dominant position of the US in the market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply-side- 70% and Demand-side 30%
• By Designation: Managers - 45%, CXOs & Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• PHC Holdings Corporation (Japan)
• Becton, Dickinson and Company (BD) (US)
• Qiagen (Germany)
• Merck KGaA (Germany)
• Labcorp (US)
• Eurofins Scientific (Luxembourg)
• Cryoport (US)
• ICON Plc (Ireland)
• Tecan Trading AG (Switzerland)
• Azenta US Inc. (US)
• Avantor, Inc. (US)
• Greiner AG (Austria)
• Amsbio (UK)
• Labcorp (US)
• Eurofins Scientific (Luxembourg)
• Hamilton Company (US)
• BioIVT LLC (US)
• BioKryo (Germany)
• ASKION GmbH (Germany)
• Sopachem (Belgium)
• Froilabo (UK)
• Cureline (US)
• SPT Labtech Ltd (UK)

Research Coverage

This research report categorizes the biobanking market by offerings [products (equipment, consumables), services (physical biobanking, virtual biobanking, other services), software]; workflow (sample collection & storage, sample processing, sample analysis, transport & logistics), operation type (manual, automated), sample type (blood products, solid tissues & organs, stem cell & cell lines, nucleic acids, biological fluids, human waste products), end user- product (biobanks, CROs), end -user services (pharma, biotech & CROs, academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biobanking market. A thorough analysis of the key industry players has provided insights into their business overview, services, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are the recent developments associated with the biobanking market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall biobanking market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (growing focus on precision medicine & population-genomics programmes, cell- & gene-therapy pipeline expansion, adoption of energy-efficient Ultra Low Temperature(ULT) freezers, end-to-end automation & robotics for physical sample handling and storage), restraints (high upfront capital expenditure, sample quality variability), opportunities ( outsourcing of cryogenic storage to third-party specialists, growing focus on sustainability and green-lab solutions), and challenges (long-term funding stability for public biobanks) influencing the growth of the market.
• Product/Service Development/Innovation: Detailed insights on newly launched products, services of the biobanking market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, services, untapped geographies, recent developments, and investments in the biobanking market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of key players including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), Cryoport (US). A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product launches, acquisitions, partnerships, agreements, collaborations, expansions, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biobanking product and service market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 BIOBANKING MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
    • 2.2.1.2 MnM repository analysis
    • 2.2.1.3 Primary interviews
    • 2.2.1.4 Insights from primary sources
  • 2.2.2 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE FORECAST
  • 2.3.1 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • 2.3.2 BIOBANKING MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
  • 3.2.1 BIOBANKING EQUIPMENT MANUFACTURERS
  • 3.2.2 BIOBANKING CONSUMABLE MANUFACTURERS
  • 3.2.3 BIOBANKING SERVICE PROVIDERS

4 PREMIUM INSIGHTS

• 4.1 BIOBANKING MARKET OVERVIEW
• 4.2 NORTH AMERICA: BIOBANKING MARKET, BY OFFERING AND COUNTRY, 2024
• 4.3 BIOBANKING PRODUCTS MARKET SHARE, BY END USER, 2024
• 4.4 BIOBANKING SERVICES MARKET SHARE, BY END USER, 2024
• 4.5 BIOBANKING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing focus on precision medicine & population genomics programs
    • 5.2.1.2 Expansion of cell & gene therapy pipeline
    • 5.2.1.3 Adoption of energy-efficient ULT freezers
    • 5.2.1.4 Integration of end-to-end automation & robotics for sample handling & storage
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital expenditure
    • 5.2.2.2 Variability associated with sample quality
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Outsourcing of activities by SME biopharma companies to third-party specialists
    • 5.2.3.2 Increasing focus on sustainability & green-lab solutions
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Challenges associated with long-term funding stability for public biobanks
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.3.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE OF BIOBANKING PRODUCTS, BY KEY PLAYER, 2024
  • 5.4.2 INDICATIVE PRICING OF BIOBANKING SERVICES, BY SERVICE TYPE, 2024
  • 5.4.3 INDICATIVE PRICING TREND FOR BIOBANKING MARKET, BY REGION, 2022-2024
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
  • 5.6.2 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFT IN BIOBANKING MARKET
• 5.7 PATENT ANALYSIS
• 5.8 LIST OF KEY PATENTS
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Automated sample collection and processing technologies
    • 5.9.1.2 Sample analysis technologies
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Data management & informatics
    • 5.9.2.2 AI & ML in biobanking
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY FRAMEWORK
    • 5.11.1.1 North America
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 TRADE ANALYSIS
  • 5.12.1 IMPORT DATA FOR HS CODE 8418, 2020-2024
  • 5.12.2 EXPORT DATA FOR HS CODE 8418, 2020-2024
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA FOR BIOBANKING PRODUCTS, BY END USER
  • 5.14.3 KEY BUYING CRITERIA FOR BIOBANKING SERVICES, BY END USER
  • 5.14.4 UNMET NEEDS & WHITE SPACES
• 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.15.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE, 2024
• 5.16 IMPACT OF AI/GEN AI ON BIOBANKING MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 USE CASES
  • 5.16.3 FUTURE OF AI IN BIOBANKING MARKET ECOSYSTEM
• 5.17 IMPACT OF 2025 US TARIFF ON BIOBANKING MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 KEY IMPACTS ON COUNTRIES/REGIONS
    • 5.17.4.1 North America
      • 5.17.4.1.1 US
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
  • 5.17.5 IMPACT ON END-USE INDUSTRIES
    • 5.17.5.1 Biobanks
    • 5.17.5.2 CROs

6 BIOBANKING MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 EQUIPMENT
    • 6.2.1.1 Freezers & refrigerators
      • 6.2.1.1.1 Storage of blood, DNA, and serum to fuel market growth
    • 6.2.1.2 Cryogenic storage systems
      • 6.2.1.2.1 Rising demand for cell & gene therapies to fuel market
    • 6.2.1.3 Alarm & monitoring systems
      • 6.2.1.3.1 Regulatory demand for continuous monitoring to support market growth
    • 6.2.1.4 Thawing equipment
      • 6.2.1.4.1 Growing demand for CAR-T and mRNA therapies to fuel uptake
    • 6.2.1.5 Temperature & humidity control systems
      • 6.2.1.5.1 Critical role in maintaining sample integrity to aid adoption
    • 6.2.1.6 Other equipment & accessories
  • 6.2.2 CONSUMABLES
    • 6.2.2.1 Surging sample volumes and recurring demand to drive market
• 6.3 SERVICES
  • 6.3.1 OUTSOURCING OF SERVICES TO CROS TO DRIVE MARKET
• 6.4 SOFTWARE
  • 6.4.1 GROWING FOCUS ON AUTOMATION TO PROPEL MARKET

7 BIOBANKING PRODUCTS MARKET FOR EQUIPMENT, BY OPERATION TYPE

• 7.1 INTRODUCTION
• 7.2 MANUAL OPERATIONS
  • 7.2.1 LARGE EXISTING INSTALLED BASE AND NO REQUIREMENT FOR SPECIALIZED LABOR TO DRIVE MARKET
• 7.3 AUTOMATED OPERATIONS
  • 7.3.1 INCREASING INNOVATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET

8 BIOBANKING PRODUCTS MARKET, BY WORKFLOW

• 8.1 INTRODUCTION
• 8.2 SAMPLE COLLECTION & STORAGE
  • 8.2.1 LARGE RESEARCH COHORTS AND SUSTAINABILITY MANDATES TO DRIVE MARKET
• 8.3 SAMPLE PROCESSING
  • 8.3.1 AUTOMATION DEMAND AND COMPLIANCE RULES TO FUEL MARKET
• 8.4 SAMPLE ANALYSIS
  • 8.4.1 HIGH DEMAND FOR ACTIONABLE DATA TO FUEL MARKET
• 8.5 TRANSPORT & LOGISTICS
  • 8.5.1 TEMPERATURE-SENSITIVE REQUIREMENTS TO SUPPORT PRODUCTS UPTAKE

9 BIOBANKING PRODUCTS MARKET, BY SAMPLE TYPE

• 9.1 INTRODUCTION
• 9.2 BLOOD PRODUCTS
  • 9.2.1 EASE OF COLLECTION AND ANALYTICAL VERSATILITY TO PROPEL MARKET
• 9.3 SOLID TISSUES & ORGANS
  • 9.3.1 GROWTH IN SPATIAL OMICS TO FUEL MARKET
• 9.4 STEM CELLS & CELL LINES
  • 9.4.1 ADOPTION OF REGENERATIVE MEDICINE TO BOOST DEMAND
• 9.5 BIOLOGICAL FLUIDS
  • 9.5.1 UTILIZATION FOR DISEASE-MECHANISM STUDIES TO FUEL UPTAKE
• 9.6 NUCLEIC ACIDS
  • 9.6.1 INTEGRATION OF MULTI-OMICS TO BOOST DEMAND
• 9.7 HUMAN WASTE PRODUCTS
  • 9.7.1 APPLICATIONS ACROSS MICROBIOME RESEARCH TO FUEL UPTAKE

10 BIOBANKING PRODUCTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 BIOBANKS
  • 10.2.1 GROWING FOCUS ON LIFE SCIENCES & CLINICAL RESEARCH TO BOOST DEMAND
• 10.3 CROS
  • 10.3.1 GROWING FOCUS ON BIOMARKER TRIALS AND OUTSOURCING OF SERVICES TO SUPPORT MARKET

11 BIOBANKING SERVICES MARKET, BY OWNERSHIP

• 11.1 INTRODUCTION
• 11.2 PRIVATE/COMMERCIAL BIOBANKS
  • 11.2.1 TECHNOLOGICALLY ADVANCED INFRASTRUCTURE AND COMPLIANCE OFFERINGS TO PROPEL MARKET
• 11.3 ACADEMIC & RESEARCH INSTITUTION BIOBANKS
  • 11.3.1 FAVORABLE FUNDING ACTIVITIES TO BOOST DEMAND
• 11.4 NATIONAL/REGIONAL AGENCIES
  • 11.4.1 GOVERNMENT FOCUS ON ADVANCING HEALTHCARE RESEARCH INITIATIVES TO DRIVE MARKET
• 11.5 HYBRID/PPP MODELS
  • 11.5.1 HIGH CREDIBILITY AND AGILITY TO SUPPORT MARKET GROWTH
• 11.6 OTHER OWNERSHIP MODELS

12 BIOBANKING MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 RESEARCH APPLICATIONS
  • 12.2.1 LIFE SCIENCE RESEARCH
    • 12.2.1.1 Increasing focus on genomics projects to fuel uptake
  • 12.2.2 CLINICAL RESEARCH
    • 12.2.2.1 Growing regulatory requirements and decentralized & hybrid trials to support market growth
• 12.3 THERAPEUTIC APPLICATIONS
  • 12.3.1 GROWING DEMAND FOR CELL & GENE THERAPIES TO PROPEL MARKET
• 12.4 DIAGNOSTIC APPLICATIONS
  • 12.4.1 REQUIREMENT OF DISEASE-SPECIFIC SAMPLES TO BOOST DEMAND
• 12.5 OTHER APPLICATIONS

13 BIOBANKING SERVICES MARKET, BY TYPE

• 13.1 INTRODUCTION
• 13.2 PHYSICAL BIOBANKING SERVICES
  • 13.2.1 MEGA-COHORTS IN ONCOLOGY & POPULATION GENOMICS TO PROPEL MARKET
• 13.3 VIRTUAL BIOBANKING
  • 13.3.1 EASE OF SPECIMEN ACCESS FOR END USERS TO DRIVE MARKET
• 13.4 OTHER SERVICES

14 BIOBANKING SERVICES MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 PHARMA-BIOTECH COMPANIES & CROS
  • 14.2.1 EXPANDING DRUG DISCOVERY & DEVELOPMENT PIPELINE TO PROPEL MARKET
• 14.3 ACADEMIC & RESEARCH INSTITUTES
  • 14.3.1 ADVANCEMENTS IN RESEARCH AND FAVORABLE GRANTS TO BOOST DEMAND
• 14.4 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 14.4.1 USE OF SAMPLES FOR THERAPEUTIC & DIAGNOSTIC PURPOSES TO AID MARKET

15 BIOBANKING MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 15.2.2 US
    • 15.2.2.1 US to dominate North American biobanking market during forecast period
  • 15.2.3 CANADA
    • 15.2.3.1 Strong public investment with national research networks and collaborations to support disease-focused biobanking
• 15.3 EUROPE
  • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 15.3.2 GERMANY
    • 15.3.2.1 High government funding and focus on advanced clinical research to augment market growth
  • 15.3.3 UK
    • 15.3.3.1 Presence of large-scale, population-based advanced research infrastructure to propel market growth
  • 15.3.4 FRANCE
    • 15.3.4.1 Growing focus on quality standards, open science, and international collaboration to support market growth
  • 15.3.5 ITALY
    • 15.3.5.1 Improved healthcare standards to support biobanking studies in cancer, rare diseases, and personalized medicine healthcare
  • 15.3.6 SPAIN
    • 15.3.6.1 Adoption of international standards and advanced government-backed infrastructure to aid market growth
  • 15.3.7 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 15.4.2 CHINA
    • 15.4.2.1 Increased research collaborations and advancements in biobank infrastructure to drive market
  • 15.4.3 JAPAN
    • 15.4.3.1 Strong genomic research output and focus on AI-driven polygenic risk scoring to boost predictive healthcare innovation
  • 15.4.4 INDIA
    • 15.4.4.1 National and disease-specific initiatives for advanced precision medicine and healthcare innovation to aid market growth
  • 15.4.5 AUSTRALIA
    • 15.4.5.1 Increasing national investments in disease-specific, microbiome, and wildlife biobanks to accelerate market growth
  • 15.4.6 SOUTH KOREA
    • 15.4.6.1 Increased quality standards and more international collaborations to support human and environmental biobanking
  • 15.4.7 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 15.5.2 BRAZIL
    • 15.5.2.1 Genetic diversity and large-scale stem cell & genomic initiatives to propel market growth
  • 15.5.3 MEXICO
    • 15.5.3.1 Favorable initiatives for improving population health research and representation in global genomic databases to drive market
  • 15.5.4 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 15.6.2 GCC COUNTRIES
    • 15.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 15.6.2.1.1 Investments in automated equipment biobank infrastructure, ISO accreditation, and Vision 2030 to boost market growth
    • 15.6.2.2 UAE
      • 15.6.2.2.1 Investments in AI-driven robotic biobanking to fuel market growth
    • 15.6.2.3 Rest of GCC countries
  • 15.6.3 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 GROWING STANDARDIZATION EFFORTS, INTERNATIONAL ACCREDITATION, AND CAPACITY-BUILDING TO PROPEL MARKET GROWTH
  • 15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
• 16.3 REVENUE ANALYSIS, 2020-2024
  • 16.3.1 REVENUE ANALYSIS FOR BIOBANKING PRODUCTS, 2020-2024
  • 16.3.2 REVENUE ANALYSIS FOR BIOBANKING SERVICES & SOFTWARE, 2020-2024
• 16.4 MARKET SHARE ANALYSIS, 2024
  • 16.4.1 MARKET SHARE ANALYSIS FOR BIOBANKING PRODUCTS, 2024
  • 16.4.2 MARKET SHARE ANALYSIS FOR BIOBANKING SERVICES & SOFTWARE, 2024
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2024
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Offering footprint
    • 16.5.5.4 Sample type footprint
    • 16.5.5.5 Workflow footprint
• 16.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 16.6.5.1 Detailed list of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of startups/ SMEs
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
  • 16.7.1 COMPANY VALUATION & FINANCIAL METRICS FOR BIOBANKING PRODUCTS MARKET
    • 16.7.1.1 Company valuation
    • 16.7.1.2 Financial metrics
  • 16.7.2 COMPANY VALUATION & FINANCIAL METRICS FOR BIOBANKING SERVICES & SOFTWARE MARKET
    • 16.7.2.1 Company valuation
    • 16.7.2.2 Financial metrics
• 16.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT/SERVICE/SOLUTION LAUNCHES
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 THERMO FISHER SCIENTIFIC INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products/Services/Solutions offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product launches
      • 17.1.1.3.2 Deals
      • 17.1.1.3.3 Expansions
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 PHC HOLDINGS CORPORATION
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products/Services/Solutions offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 BECTON, DICKINSON AND COMPANY (BD)
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products/Services/Solutions offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product launches
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses & competitive threats
  • 17.1.4 QIAGEN
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products/Services/Solutions offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Product launches
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 MERCK KGAA
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products/Services/Solutions offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Expansions
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Key strengths
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses & competitive threats
  • 17.1.6 AVANTOR, INC.
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products/Services/Solutions offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Deals
      • 17.1.6.3.2 Expansions
  • 17.1.7 CRYOPORT
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products/Services/Solutions offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches
      • 17.1.7.3.2 Deals
      • 17.1.7.3.3 Expansions
  • 17.1.8 TECAN TRADING AG
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products/Services/Solutions offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Product launches
  • 17.1.9 AZENTA US INC.
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products/Services/Solutions offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product launches
      • 17.1.9.3.2 Deals
      • 17.1.9.3.3 Expansions
  • 17.1.10 GREINER AG
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products/Services/Solutions offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Product launches
      • 17.1.10.3.2 Expansions
  • 17.1.11 AGILENT TECHNOLOGIES, INC.
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products/Services/Solutions offered
  • 17.1.12 LABCORP
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products/Services/Solutions offered
    • 17.1.12.3 Recent developments
      • 17.1.12.3.1 Deals
  • 17.1.13 EUROFINS SCIENTIFIC
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products/Services/Solutions offered
• 17.2 OTHER PLAYERS
  • 17.2.1 HAIER BIOMEDICAL
  • 17.2.2 HAMILTON COMPANY
  • 17.2.3 AMSBIO
  • 17.2.4 BAY BIOSCIENCES
  • 17.2.5 BIOKRYO
  • 17.2.6 SPT LABTECH LTD.
  • 17.2.7 ASKION GMBH
  • 17.2.8 CTIBIOTECH
  • 17.2.9 CURELINE
  • 17.2.10 FIRALIS MOLECULAR PRECISION
  • 17.2.11 SOPACHEM
  • 17.2.12 FROILABO
  • 17.2.13 BIOIVT

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS